Single Dose Preoperative Administration of Intravenous Iron Corrects Iron Deficiency Anaemia in Colorectal Cancer

J A D Simpson1*, S L Ng1, M J Brookes2 and A G Acheson1

1Division of Gastroenterological Disease, Department of Surgery, Queens Medical Centre Campus, Nottingham University Hospitals, Nottingham, NG7 2UH
2Gastroenterology Unit, Royal Wolverhampton NHS Trust Wednesfield Road, Wolverhampton, WV10 0QP

Abstract

Preoperative iron deficiency anaemia (IDA) is common and associated with poor postoperative outcomes. Standard treatment includes allogenic blood transfusion or oral iron supplementation, but new intravenous iron strategies have shown promise in the perioperative setting. We aim to assess the feasibility and effect of a single dose of intravenous iron in treating preoperative colorectal cancer related anaemia.

We performed an open labelled phase I uncontrolled trial. Patients with a diagnosis of colorectal cancer and biochemically proven IDA received intravenous iron a minimum of 14 days prior to surgery. Blood parameters including haemoglobin values were measured at pre-dose and preoperative time points.

Eight of the ten patients responded to intravenous iron supplementation with a mean preoperative rise in haemoglobin of 1.1 g/dl (p=0.036). Ferritin levels rose by a mean of 523.4ng/ml across the ten patients. No adverse events occurred in any of the trial patients.

This trial demonstrates that intravenous iron is both a feasible and effective treatment for IDA in anaemic colorectal cancer patients. However two patients did not respond to treatment, highlighting the need to identify biochemical markers which will accurately predict the underlying cause for anaemia and response to treatment.

Keywords: Anaemia; Intravenous; Iron; Colorectal; Cancer

Introduction

Preoperative iron deficiency anaemia (IDA) is common and is associated with increased need for allogenic blood transfusion and poor post operative outcomes [1,2]. Treatment of IDA is associated with a reduction in the need for blood transfusion in the perioperative period [3]. Treatment strategies include iron supplementation via either an enteral or parenteral route. The use of new intravenous formulations in the gynaecological setting suggest that it may be as effective as oral iron but without the associated gastrointestinal side effects reported in some patients [4]. It has also been shown to be effective within a 14 day time period, suggesting that it could form a pragmatic part of an Enhanced Recovery after Surgery (ERAS) protocol while at the same time not delaying treatment targets. Intravenous iron has previously been shown to be effective in both solid organ and haematological malignancies, particularly when administered with erythropoietic stimulating agents [5,6]. Repeat dosing of intravenous iron in colorectal cancer patients has been shown to be effective [7] but single dose administration that can form part of the preoperative work up has not been tested [8]. Patients suffering from colorectal malignancy are typically over fifty-five years of age, are commonly immunosuppressed due to the inflammatory nature of the cancer and may be undernourished. It may be more difficult for this group of patients to mount an erythropoeitic response in the face of supplemental iron therapy.

Furthermore, the type of anaemia manifest in colorectal cancer patients is typically assumed to be IDA however it is common for this group of patients to present with inflammatory related anaemia of chronic disease (ACD) [9]. The underlying cause of their anaemia is likely to dictate their response to treatment. The liver hormone hepcidin has recently been identified as central iron stores regulator [10] and it has been suggested that this may offer a more accurate representation of iron mobilisation from stores than current biochemical markers and could therefore predict response to treatment.

Aim

To assess the feasibility and effectiveness of a single dose of intravenous iron in treating preoperative colorectal cancer related anaemia.

Method

We performed an open labelled phase I uncontrolled trial, designed to determine the preoperative effect of intravenous iron. Ten patients with histologically proven colorectal cancer and biochemically diagnosed IDA were prospectively selected to receive preoperative Intravenous iron. IDA was defined as a haemoglobin (Hb)<13.0g/dl in males and a Hb<11.5g/dl in females, in combination with a serum ferritin level <20ng/ml, this was consistent with the local laboratory lower limit of normal range.

A minimum of 14 days prior to surgery each patient received a single administration of intravenous iron dextran (Cosmofer). Iron dosage was calculated using the manufacturer’s established protocol based on Body Mass Index and baseline Hb measurement (max dose 1.5g). Haemoglobin and Ferritin measurements were recorded immediately prior to iron administration and on the day before operation. Patients initially received a 25mg test dose over 15
minutes, following this infusion was stopped and temperature, blood pressure and pulse were recorded every 15 minutes for the next 60 minutes. If no adverse reaction was detected the remaining infusion commenced at a rate of 200mg over 60 minutes and then increased to 300mg/hour. Temperature, blood pressure and pulse were recorded every 30 minutes. The intravenous cannula was flushed with normal saline prior to removal. The primary outcome measure was preoperative change in haemoglobin concentration, secondary outcomes included length of hospital stay, transfusion requirements and postoperative morbidity and mortality. Wilcoxon signed rank test was used to compare baseline and preoperative haemoglobin values.

Results

Nine males and one female were recruited with a mean age of 73.5 (SD +/- 9.1) years. The calculated dose of intravenous iron, tumour stage and location, and primary and secondary endpoints are detailed in Table 1. Only one patient received preoperative chemoradiotherapy and none of the patients required a preoperative blood transfusion following administration of intravenous iron.

The mean baseline Haemoglobin was 10.1g/dL (range 7.1 -12.6g/dL). Following IV iron administration a significant mean rise of 1.1g/dL (range -0.8 -3.8g/dL) in Haemoglobin was seen over an average time period of 27 days (p=0.0359). Resulting in a mean preoperative Hb of 11.2g/dL (range 9.6 -13.3g/dL) (Figure 1a). Out of the ten patients, two did not respond to intravenous iron. Patients 5 and 8 showed a drop in haemoglobin level over the course of treatment by 0.6 and 0.3g/dL respectively. Ferritin levels rose by a mean of 523.4ng/ml across the ten patients as illustrated in (Figure 1b).

Comparison of the baseline haemoglobin with the respective change in haemoglobin post dosing for each patient demonstrates an inverse relationship (Figure 1c). No adverse events occurred in any of the trial patients as a result of receiving intravenous iron. The median length of postoperative hospital stay was 8.5 days and a total of five units of red blood cells were transfused in four of the ten patients. All transfusion products were given intraoperatively. None of the patients received alternative transfusion products or erythropoietin supplementation. Two patients developed postoperative complications: one experienced a respiratory acidosis and associated atrial flutter but made a full recovery prior to discharge. The second patient developed multi organ failure following acute onset small bowel obstruction and died on the thirteenth postoperative day.

| Patient | Baseline Haemoglobin (g/dL) | Preoperative Haemoglobin (g/dL) | Change in Haemoglobin (g/dL) | Dose of Cosmofer (mg) | Location of Tumour | Histopathology (TNM classification) | Length of Stay (days) | Perioperative transfusion rate (No. Of units) | 30 day postoperative morbidity | 30 day postoperative mortality |
|---------|-----------------------------|--------------------------------|----------------------------|----------------------|-------------------|-----------------------------------|----------------------|--------------------------------------------|-------------------------------|-------------------------------|
| 1       | 9.9                         | 10.2                           | 0.3                        | 1295                 | Left colon        | T,N,M,i                          | 16                   | 1                                          | Respiratory acidosis and atrial flutter | No                            |
| 2       | 7.1                         | 10.4                           | 3.3                        | 1500                 | Transverse colon  | T,N,M,i                          | 13                   | 2                                          | N/A                           | No                            |
| 3       | 9.7                         | 12                             | 2.3                        | 1200                 | Right colon       | T,N,M,i                          | 6                    | 0                                          | N/A                           | No                            |
| 4*      | 12.6                        | 13.3                           | 0.7                        | 800                  | Rectum            | T,N,M,i                          | 10                   | 0                                          | N/A                           | No                            |
| 5       | 11                          | 10.4                           | -0.6                       | 1300                 | Right colon       | T,N,M,i                          | 7                    | 0                                          | N/A                           | No                            |
| 6       | 10                          | 10.3                           | 0.3                        | 900                  | Right colon       | T,N,M,i                          | 6                    | 1                                          | N/A                           | No                            |
| 7       | 12                          | 12.7                           | 0.7                        | 800                  | Right colon       | T,N,M,i                          | 6                    | 0                                          | N/A                           | No                            |
| 8       | 12.1                        | 11.8                           | -0.3                       | 900                  | Transverse colon  | TVA with high grade dysplasia   | 13                   | 0                                          | Multi-organ failure secondary to SBO | Yes                           |
| 9       | 8.1                         | 9.6                            | 1.5                        | 1360                 | Rectum            | T,N,M,i                          | 1                    | 0                                          | N/A                           | No                            |
| 10      | 8.6                         | 11.4                           | 2.8                        | 880                  | Right colon       | T,N,M,i                          | 11                   | 1                                          | N/A                           | No                            |
| Mean    | 10.1                        | 11.2                           | 1.1                        | 1093.5               |                   |                                   |                      |                                            | 8.9                           |                               |

Table 1: Patient baseline, preoperative and change in haemoglobin values, Intravenous iron dose, Location and stage of tumour, Length of hospital stay, Transfusion rate, 30 day postoperative morbidity and mortality. TVA (Tubulovillous adenoma), SBO (Small bowel obstruction), *denotes patient receiving preoperative chemotherapy.

Figure 1a: A box plot demonstrating minimum, maximum, median and interquartile values for serum ferritin concentrations as measured before dosing with intravenous iron and immediately preoperatively.

Figure 1b: A box plot demonstrating minimum, maximum, median and interquartile values for haemoglobin concentration as measured before dosing with intravenous iron and immediately preoperatively.
Discussion

This open label prospective study demonstrates that preoperative single dose administration of intravenous iron is both feasible and efficacious in anemic colorectal cancer patients. The use of intravenous iron produced a mean 1.1g rise in haemoglobin over two preoperative weeks. These results support those previously reported by Munoz et al who demonstrated improvement in haemoglobin concentration in 30 colorectal cancer patients receiving preoperative iron sucrose (200 mg/ twice a week; 4-8 sessions) [7]. In contrast [11] concluded, that there is no support for intravenous iron sucrose as a preoperative adjunct in colorectal adenocarcinoma to increase haemoglobin levels. However, concerns regarding the study design and the ability to justify these conclusions have been raised [12]. It is crucial to establish the haemoglobin and iron status in order to determine the efficacy of intravenous iron. In Edwards study only nine patients in each group had a below normal haemoglobin, and in these patients receiving intravenous iron the mean ferritin was 100.5ng/ml with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%. The parameters listed in the iron intervention group represent a phenotype more consistent with a mean transferrin saturation of 11.0%.

Interestingly the change in haemoglobin concentration following administration of intravenous iron was inversely proportional to the starting concentration. Although we did not measure erythropoietin levels during the study this may in part explain the observed relationship. De Klerk et al. [14] have previously demonstrated an inverse relationship between Hb levels and serum erythropoietin titres in an in vitro model of anaemia. Furthermore, a number of studies have demonstrated improved response in Hb concentration when intravenous iron and erythropoietin are given in combination compared to when either is given alone, particularly in chemotherapy and chronic renal disease related anaemia [6,15]. Therefore those patients with more severe IDA are likely to have the highest serum erythropoietin levels, following administration of intravenous iron this leads to improved utilisation of these building blocks by the bone marrow and ultimately a greater rise in Hb concentration.

However, a recent Cochrane review of the pre and peri-operative use of erythropoietin supplementation in colorectal cancer patients concluded that there was no robust evidence to support its use in this group and that in particular it had no effect on reducing allogenic blood transfusion [16]. Although this systematic review did not highlight an increase in mortality or thrombotic events in the intervention groups, there have been a number of trials that have reported an increase in thrombotic events, decreased survival and poor tumour control following administration of erythropoiesis stimulating agents in cancer patients, particularly if it is given in conjunction with chemotherapy regimens [17,18].

It is also important to note that two patients in this trial failed to respond to intravenous iron therapy. Excessive ongoing blood loss was considered because this may have blunted the effect of intravenous iron. Rectal blood loss was not directly quantified but clinical review in the pre-operative period, by both the study team and the patient’s medical team, did not find excessive per rectal bleeding in either patient. This raises the possibility that they may be suffering from a functional iron deficiency where the problem is not reduced iron stores but the inability to make available and utilise iron. The relatively recent discovery of the liver hormone, hepcidin, and its role in iron homeostasis may lead to the development of a chemical biomarker which will allow clinicians to predict response to iron therapy in the future. Early studies have indicated a relationship between hepcidin expression and anaemia associated with both solid organ and haematological tumours [19,20], but a connection between hepcidin expression and inflammatory induced anaemia in colorectal cancer is yet to be established. However, it has been suggested that hepcidin has a role to play in the oncogenic signalling pathways of colorectal cancer [21].

It is clear that preoperative anaemia is associated with the need for allogenic blood transfusion and poor post operative outcomes [1,2]. Although this study confirms that intravenous iron did not result in any adverse events and could be used to treat preoperative anaemia in this small group of non-symptomatic colorectal cancer patients, whether this can improve postoperative complications or reduce the need for peri-operative blood transfusion rates remain to be seen. Indeed we hope that this study informs the design of larger randomised controlled trials to determine the effect of intravenous iron on postoperative endpoints including length of stay, postoperative mortality and morbidity.

References

1. Beattie WS, Karkouti K, Wijeysundera DN, Tall G (2009) Risk associated with preoperative anaemia in noncardiac surgery: a single-centre cohort study. Anesthesiology 110: 574-581.
2. Wu WC, Schiffner TL, Henderson WG, Eaton CB, Poses RM, et al. (2007) Preoperative haematocrit levels and postoperative outcomes in older patients undergoing noncardiac surgery. JAMA 297: 2481-2488.
3. Lidder PG, Sanders G, Whitehead E, Douie WJ, Mellor N, et al. (2007) Preoperative oral iron supplementation reduces blood transfusion in colorectal surgery – a prospective, randomised, controlled trial. Ann R Coll Surg Eng 89: 418-421.
4. Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, et al. (2009) Large-dose intravenous ferric carboxymaltose injection for iron deficiency anaemia in heavy uterine bleeding: a randomised, controlled trial. Transfusion 49: 2719-2728.
5. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, et al. (2004)
Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22: 1301-1307.

6. Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12: 231-242.

7. Muñoz M, García-Erce JA, Díez-Lobo Al, Campos A, Sebastianes C, et al. (2009) Usefulness of the administration of intravenous iron sucrose for the correction of preoperative anemia in major surgery patients. Med Clin (Barc) 132: 303-306

8. Beris P, Muñoz M, García-Erce JA, Thomas D, Maniatis A, et al. (2008) Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth 100: 599-604.

9. Littlewood TJ, Alikhan R (2008) The use of intravenous iron in patients with cancer-related anaemia. Br J Haem 141: 751-756.

10. Ganz T (2006) Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program 507: 29-35.

11. Edwards TJ, Noble EJ, Durrant A, Mellor N, Hosie KB (2009) Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. Br J Surg 96: 1122-1128.

12. Simpson JA, Tselepis C, Iqbal T, Acheson AG, Brookes MJ (2010) Letter 2: Randomized clinical trial of preoperative intravenous iron sucrose to reduce blood transfusion in anaemic patients after colorectal cancer surgery. Br J Surg 97: 298-299.

13. Goddard AF, James MW, Macintyre AS, Scott BB (2005) Guidelines for the management of iron deficiency anaemia. BSG Guidelines in Gastroenterology May: 1-8.

14. de Klerk G, Rosengarten PCJ, Vet RJWM, Goudsmit R (1981) Serum Erythropoietin (ESF) Tilters in Anaemia. Blood 58: 1164-1170.

15. Hedenus M, Birgegård G, Näslund P, Ahlberg L, Karlsson T, et al. (2007) Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21: 627-32.

16. Devon KM, McLeod RS. (2009) Pre and peri-operative erythropoietin for reducing allogepic blood transfusions in colorectal cancer surgery. Cochrane Database Syst Rev 21: CD007148.

17. Juneja V, Keegan P, Gootenberg JE, Rothmann MD, Shen YL, et al. (2008) Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res 14: 3242-3247.

18. Roddy JV, Partridge SM, Rockey ML, Pruenemer JM, Guo JJ, et al. (2010) Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents. Am J Clin Oncol 33: 36-42.

19. Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, et al. (2008) Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res 14: 3262-3267.

20. Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, et al. (2005) Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood 105: 1797-17802.

21. Ward DG, Roberts K, Brookes MJ, Joy H, Martin A, et al. (2008) Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol 14: 1339-1345.